Applied Materials’ (NASDAQ: AMAT) earnings and revenue for the third quarter exceeded the market’s views. Adjusted EPS of $1.06 and revenue of $4.40 billion in Q3, grew 43% and 23%, respectively and beat the consensus targets. AMAT stock rose about 1% in the after-market hours.
On a GAAP basis, earnings grew 49% to $0.91 per share. The company returned $402 million to shareholders including $200 million in share repurchases and dividends of $202 million.
The Santa Clara, California-based semiconductor firm expects sales in the fourth quarter of 2020 to be approximately $4.60 billion, plus or minus $200 million. Non-GAAP EPS is expected to be in the range of $1.11 to $1.23.
AMAT stock had advanced 7% since the beginning of this year and 35% in the last 12 months.
Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings
Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key